This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

John I. Levitt, MD

JAMA. 1970;211(12):2014-2015.

Abstract
Administration of spironolactone in standard dosage to nine women with mild renal disease resulted in amenorrhea in six and marked menstrual irregularity in a seventh. Discontinuation of therapy resulted in normal menstrual periods within two months in every patient. The drug action causing this side effect may be responsible for previously reported gynecomastia, but this action is unknown. The high incidence of amenorrhea in this group may be due to increased drug susceptibility or decreased drug elimination in patients with kidney disease.

Author Affiliations
From the Department of Internal Medicine, University of Minnesota Medical School, Minneapolis.

Footnotes
Reprint requests to Box 240, University of Minnesota Medical School, Minneapolis 55455 (Dr. Levitt).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

New Activity of Spironolactone: Inhibition of Angiogenesis In Vitro and In Vivo
Klauber et al.
Circulation 1996;94:2566-2571.
ABSTRACT | FULL TEXT  

Cardiovascular Drugs and Sexuality: A Cardiologist's Review
Papadopoulos
Arch Intern Med 1980;140:1341-1345.
ABSTRACT  

Spironolactone and Endocrine Dysfunction
LORIAUX et al.
ANN INTERN MED 1976;85:630-636.
ABSTRACT  

Adverse Reactions to Spironolactone: A Report From the Boston Collaborative Drug Surveillance Program
Greenblatt and Koch-Weser
JAMA 1973;225:40-43.
ABSTRACT  

Gynecomastia and Impotence Complications of Spironolactone Therapy
Greenblatt and Koch-Weser
JAMA 1973;223:82-82.
ABSTRACT